A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer

Launched by MEMORIAL SLOAN KETTERING CANCER CENTER · Feb 20, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how exercise therapy, specifically regular walking on a treadmill, affects signs of prostate cancer in men who have low-risk localized prostate cancer and are currently under active surveillance. This means they are closely monitored by their doctors but are not receiving treatment at this time. The researchers want to see if the exercise therapy can have a positive impact on the cancer indicators compared to participants who continue their usual exercise routines.

To be eligible for this study, participants must be men aged 18 or older with confirmed localized prostate cancer and not currently active in any exercise programs. They should also be relatively inactive, meaning they do not meet the recommended exercise guidelines. Participants will undergo an evaluation by an exercise physiologist to ensure they are safe to join the study. It’s important to note that this study does not provide direct treatment for prostate cancer; rather, it aims to understand the potential benefits of exercise in managing the condition.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18
• • Men with histologically confirmed localized prostate cancer undergoing active surveillance.
• • Inactive, defined as not meeting the national exercise guidelines for cancer patients (\<150 minutes/week of moderate or vigorous exercise)43 as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry (general physical activity screening assessment via smart watch).
• • Screening clearance by an MSK Exercise Physiologist (i.e., review of ECG)
• • BMI \<40 kg/m\^2
• • Cleared for exercise participation as per pre-screening clearance via the Physical Activity Readiness Questionnaire (PAR-Q+) (Appendix B)
• Exclusion Criteria:
• • Enrollment in any other program that may alter the impact of exercise on tumor outcomes (e.g., weight loss program)
• • Any neoadjuvant anticancer treatment of any kind for prostate cancer in the last 5 years
• • Any history of systemic anticancer therapy in the last 15 years
• • Distant metastatic malignancy of any kind
• • Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation